**Abstract**

**Purpose:** This study investigated the pharmacokinetics of mirtazapine (MIR) and its hydroxylated metabolite in Japanese psychiatric patients.

**Patients and Methods:** The subjects were 59 Japanese patients treated with racemic MIR. The steady-state plasma concentrations of MIR and N-desmethylmirtazapine (DMIR), 8-hydroxy-MIR (8-OH-MIR) were measured using high performance liquid chromatography. CYP2D6 genotypes were determined by polymerase chain reaction. Three subjects whose plasma levels of MIR and DMIR were below the limit of detection were regarded as non-adherent and excluded. Multiple regression analysis (stepwise method) was performed to analyze the relationship between subject-independent variables (gender, age, smoking status and number of mutated CYP2D6 alleles) and subject-dependent variables such as plasma concentrations of MIR, DMIR, 8-OH-MIR (ng/ml/mg/kg; all corrected for dose and body weight) and 8-OH-MIR/MIR ratio.

**Results:** Multiple regression analysis revealed that smoking (p=0.016) and gender (p=0.041) had a significant impact on plasma concentrations of MIR. The final models were described by the following equations: Plasma concentration of MIR = 86.6 - 31.9 ×smoking status (smoking=1, non-smoking=0) - 23.0 × gender (male=1, female=0) (R= 0.45, p=0.002, coefficient of determination (R^2^) =0.20). Smoking status was a significant factor correlated to plasma concentration of 8-OH-MIR (p=0.034). The final model was described by the following equation: Plasma concentration of 8-OH-MIR (corrected for dose and body weight) = 2.41 - 1.59×smoking status (smoking=1, non-smoking=0) (R= 0.29, p=0.034, R^2^=0.08). There were no significant factors correlated to in 8-OH-MIR/MIR ratio in the multiple regression analysis.

**Conclusion:** Gender and smoking polymorphism might affect pharmacokinetics of racemic MIR in Japanese patients.
